Baseline albumin and neutrophil-to-lymphocyte ratio as predictive biomarkers of response to platinum-based therapy in patients with highly proliferative neuroendocrine carcinomas

#3246

Introduction: Neuroendocrine carcinomas (NECs) with ki-67/MIB1>55% show different responses to platinum-based therapy. Loss of Rb protein and KRAS mutation are markers of response, but it is unknown whether also clinical factors may have a predictive role.

Aim(s): We explored inflammatory and nutritional factors at baseline in order to identify biomarkers related with response, toxicities and outcomes.

Materials and methods: We identified patients (pts) with advanced NECs treated with cisplatin (CP) or carboplatin (CB) and etoposide in 2015-19 at a tertiary referral centre. Linear and Cox regressions were used to investigate numeric and time-to-event outcomes. Maximization of log-rank statistics was used for optimal cutoffs finding.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Colombo E

Authors: Colombo E, Manca P, Prinzi N, Torchio M, Corti F,

Keywords: neuroendocrine carcinoma, albumin, neutrophil-to-lymphocyte ratio, neutropenia, platinum-based therapy, predictive biomarker, clinical biomarker, NECs,